Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) Income from Continuing Operations (2016 - 2025)

Dare Bioscience (DARE) has disclosed Income from Continuing Operations for 8 consecutive years, with 3672148.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 21.56% year-over-year to 3672148.0, compared with a TTM value of 17446692.0 through Sep 2025, up 25.3%, and an annual FY2024 reading of 23451485.0, up 24.2% over the prior year.
  • Income from Continuing Operations was 3672148.0 for Q3 2025 at Dare Bioscience, up from 3827800.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 384322.0 in Q2 2022 and bottomed at 16230567.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 7211834.95, with a median of 7359466.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations soared 104.19% in 2022, then crashed 2439.02% in 2023.
  • Year by year, Income from Continuing Operations stood at 9543115.0 in 2021, then plummeted by 70.08% to 16230567.0 in 2022, then surged by 68.14% to 5171460.0 in 2023, then decreased by 4.19% to 5388197.0 in 2024, then soared by 31.85% to 3672148.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for DARE at 3672148.0 in Q3 2025, 3827800.0 in Q2 2025, and 4558547.0 in Q1 2025.